Globally Sirtex Achieves 36 Consecutive Quarters of Dose Sales Growth
Woburn, Mass. — Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), a leading manufacturer of targeted, innovative liver cancer therapies, recently announced dose sales of SIR-Spheres microspheres grew a solid 21 percent with more than 4,750 doses being supplied in the Americas region for the year ending June 30, 2013.
"The Americas continued to experience outstanding sales growth over the past year opening more than 50 new accounts in the U.S. and successfully expanding operations into Latin America. We expect increased demand for this important treatment option for patients with metastatic colorectal cancer as we continue to educate the oncology patient and physician communities about SIR-Spheres microspheres," said Mike Mangano, president of Sirtex Medical. "Additionally in 2013, we reached a key research milestone with the completion of patient recruitment into our landmark SIRFLOX study. We continue to invest throughout our business to prepare for the results from this study in 2014, as well as to accommodate our expanding base in the U.S. and anticipated growth in Latin America and Canada."
Globally, revenue was $100 million Australian dollars, up 16 percent from 2012, with net profit after tax of AU$18 million. Dose sales of SIR-Spheres microspheres grew 19 percent in fiscal year 2013, with Asia Pacific reporting growth of 29 percent and Europe, Middle East and Africa increasing nine percent. Sirtex plans to triple manufacturing capacity in 2014 with new facilities in Germany and the U.S.
For more information visit www.Sirtex.com or find the latest updates on the SIR-Spheres microspheres Facebook page.
About Selective Internal Radiation Therapy using SIR-Spheres microspheres
Selective Internal Radiation Therapy (SIRT), also known as radioembolization, is a proven technology for inoperable liver cancer that delivers doses of radiation directly to the site of tumors. In a minimally invasive treatment, millions of radioactive SIR-Spheres microspheres are infused via a catheter into the liver where they selectively target liver tumors with a dose of internal radiation up to 40 times higher than conventional radiotherapy, while sparing healthy tissue.
Clinical studies have confirmed that patients with metastatic colorectal cancer treated with SIR-Spheres microspheres have response rates higher than with other forms of treatment, resulting in increased life expectancy, greater periods without tumor activity and improved quality of life. SIRT has been found to shrink liver tumors more than chemotherapy alone.
SIR-Spheres microspheres are approved for use in Australia, the United States of America (FDA PMA approval), the European Union (CE Mark) and Argentina (ANMAT). Additionally, SIR-Spheres microspheres are supplied in countries such as Hong Kong, Malaysia, Singapore, Thailand, Taiwan, India, Israel, and Turkey. Available at more than 600 treatment centers, over 34,000 doses of SIR-Spheres microspheres have been supplied worldwide.
For more information, visit www.sirtex.com.
SIR-Spheres(R) is a registered trademark of Sirtex SIR-Spheres Pty Ltd.
CONTACT: Sirtex Medical Inc.
Elizabeth Romero, 919-457-0749